AR055601A1 - Compuestos derivados de imidazopiridina como ligandos de receptores canabinoides - Google Patents
Compuestos derivados de imidazopiridina como ligandos de receptores canabinoidesInfo
- Publication number
- AR055601A1 AR055601A1 ARP060103437A ARP060103437A AR055601A1 AR 055601 A1 AR055601 A1 AR 055601A1 AR P060103437 A ARP060103437 A AR P060103437A AR P060103437 A ARP060103437 A AR P060103437A AR 055601 A1 AR055601 A1 AR 055601A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- substituted
- unsubstituted
- cycloalkyl
- membered
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 9
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 3
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- -1 imidazopyridine compound Chemical class 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 1
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 abstract 1
- 102000018208 Cannabinoid Receptor Human genes 0.000 abstract 1
- 108050007331 Cannabinoid receptor Proteins 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 238000013329 compounding Methods 0.000 abstract 1
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 208000026278 immune system disease Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 201000008482 osteoarthritis Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Composicion farmacéutica que lo compende y su uso para la fabricacion de un medicamento util para el tratamiento de una afeccion mediada por la actividad de receptores de cannabinoides de tipo 2, tal como trastorno inmune, trastorno inflamatorio, dolor, artritis reumatoide, esclerosis multiple, osteoartritis u osteoporosis. Reivindicacion 1. un compuesto de imidazopiridina caracterizado porque es de formula (1) en la que: X1 es NR4 u O; R1 se selecciona entre H, alquilo C1-6, cicloalquilo C3-6 y halo-alquilo C1-6 sustituido; R2 es H o (CH2)mR3 donde m es 0 o 1; o R1 y R2 junto con el átomo de N al que están unidos forman un anillo heterociclilo de 4 a 8 miembros no aromático opcionalmente sustituido; R3 es un grupo heterociclilo de 4 a 8 miembros no aromático, un grupo cicloalquilo C3-8, alquilo C1-10 lineal o ramificado, alquenilo C2-10, cicloalquenilo C3-8, alquinilo C2-10, cicloalquinilo C3-8 o un grupo fenilo, pudiendo estar cualquiera de ellos sin sustituir o sustituido, o R5; R4 se selecciona entre H, alquilo C1-6, cicloalquilo C3-6, alquilo C1-6 sustituido con halo, COCH3, y SO2Me; R5 es como se muestra en formula (2) donde p es 0, 1 o 2, y X es CH2, O, S o SO2; R6 es fenilo sin sustituir o sustituido, cicloalquilo C3-6 sin sustituir o sustituido o un anillo heterociclilo no aromático de 4 a 8 miembros sin sustituir o sustituido; R7 es OH, alcoxi C1-6, NR8aR8b, NHCOR9, NHSO2R9 o SOqR9; R8a es H o alquilo C1-6; R8b es H o alquilo C1-6; R9 es alquilo C1-6; R10 es H, alquilo C1-6 sustituido o sin sustituir o Cl; R12 es H o alquilo C1-6; R13 es H o alquilo C1-6; q es 0, 1 o 2; o un derivado farmacéuticamente aceptable del mismo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0516380A GB0516380D0 (en) | 2005-08-09 | 2005-08-09 | Compounds |
| GB0524324A GB0524324D0 (en) | 2005-11-29 | 2005-11-29 | Compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR055601A1 true AR055601A1 (es) | 2007-08-29 |
Family
ID=37192394
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060103437A AR055601A1 (es) | 2005-08-09 | 2006-08-07 | Compuestos derivados de imidazopiridina como ligandos de receptores canabinoides |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20080221097A1 (es) |
| EP (1) | EP1912985A1 (es) |
| JP (1) | JP2009504587A (es) |
| KR (1) | KR20080034457A (es) |
| AR (1) | AR055601A1 (es) |
| AU (1) | AU2006278191A1 (es) |
| BR (1) | BRPI0614272A2 (es) |
| CA (1) | CA2618165A1 (es) |
| CR (1) | CR9787A (es) |
| EA (1) | EA200800562A1 (es) |
| IL (1) | IL188924A0 (es) |
| MA (1) | MA29694B1 (es) |
| MX (1) | MX2008001935A (es) |
| NO (1) | NO20081195L (es) |
| PE (1) | PE20070239A1 (es) |
| TW (1) | TW200734335A (es) |
| WO (1) | WO2007017237A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0705803D0 (en) * | 2007-03-28 | 2007-05-02 | Glaxo Group Ltd | Novel compounds |
| WO2010113834A1 (ja) | 2009-03-30 | 2010-10-07 | アステラス製薬株式会社 | ピリミジン化合物 |
| WO2011097553A1 (en) | 2010-02-08 | 2011-08-11 | Allergan, Inc. | Pyridazine derivatives useful as cannabinoid - 2 agonists |
| BR112013003481A8 (pt) * | 2010-07-29 | 2017-12-26 | Astellas Pharma Inc | composto fundido a anel de piridina |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3379404D1 (en) * | 1982-12-29 | 1989-04-20 | Kureha Chemical Ind Co Ltd | Cephalosporin derivatives |
| US5112820A (en) * | 1990-03-05 | 1992-05-12 | Sterling Drug Inc. | Anti-glaucoma compositions containing 2- and 3-aminomethyl-6-arylcarbonyl- or 6-phenylthio-2,3-dihydropyrrolo-(1,2,3-de)-1,4-benzoxazines and method of use thereof |
| FR2692575B1 (fr) * | 1992-06-23 | 1995-06-30 | Sanofi Elf | Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
| US6696448B2 (en) * | 1996-06-05 | 2004-02-24 | Sugen, Inc. | 3-(piperazinylbenzylidenyl)-2-indolinone compounds and derivatives as protein tyrosine kinase inhibitors |
| ATE237023T1 (de) * | 1998-01-23 | 2003-04-15 | Voith Paper Patent Gmbh | Verfahren zur entfernung von feinen verunreinigungen aus einer faserstoffsuspension |
| US6232320B1 (en) * | 1998-06-04 | 2001-05-15 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
| US7332494B2 (en) * | 2000-08-14 | 2008-02-19 | Janssen Pharmaceutica, N.V. | Method for treating allergies using substituted pyrazoles |
| WO2002020002A2 (en) * | 2000-09-06 | 2002-03-14 | Ortho Mcneil Pharmaceutical, Inc. | A method for treating allergies |
| US20040063744A1 (en) * | 2002-05-28 | 2004-04-01 | Tao Wang | Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides |
| EP1534687B1 (en) * | 2002-08-21 | 2006-09-27 | Glaxo Group Limited | 2-phenylamino-4-trifluoromethyl-5-(benzyl- or pyridin-4-ylmethyl)carbamoylpyrimidine derivatives as selective cb2 cannabinoid receptor modulators |
| GB0222493D0 (en) * | 2002-09-27 | 2002-11-06 | Glaxo Group Ltd | Compounds |
| AU2004213375A1 (en) * | 2003-02-14 | 2004-09-02 | Wyeth | Heterocyclyl-3-sulfonylazaindole or -azaindazole derivatives as 5-Hydroxytryptamine-6 ligands |
| US20040214856A1 (en) * | 2003-04-23 | 2004-10-28 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
| EP1753764B1 (en) * | 2004-06-09 | 2008-10-29 | Glaxo Group Limited | Pyrrolopyridine derivatives |
-
2006
- 2006-08-07 AR ARP060103437A patent/AR055601A1/es unknown
- 2006-08-07 MX MX2008001935A patent/MX2008001935A/es unknown
- 2006-08-07 US US11/997,918 patent/US20080221097A1/en not_active Abandoned
- 2006-08-07 AU AU2006278191A patent/AU2006278191A1/en not_active Abandoned
- 2006-08-07 KR KR1020087003128A patent/KR20080034457A/ko not_active Application Discontinuation
- 2006-08-07 JP JP2008525462A patent/JP2009504587A/ja not_active Withdrawn
- 2006-08-07 EA EA200800562A patent/EA200800562A1/ru unknown
- 2006-08-07 EP EP06763009A patent/EP1912985A1/en not_active Withdrawn
- 2006-08-07 CA CA002618165A patent/CA2618165A1/en not_active Abandoned
- 2006-08-07 BR BRPI0614272-9A patent/BRPI0614272A2/pt not_active Application Discontinuation
- 2006-08-07 WO PCT/EP2006/007812 patent/WO2007017237A1/en active Application Filing
- 2006-08-07 TW TW095128913A patent/TW200734335A/zh unknown
- 2006-08-07 PE PE2006000952A patent/PE20070239A1/es not_active Application Discontinuation
-
2008
- 2008-01-21 IL IL188924A patent/IL188924A0/en unknown
- 2008-02-08 MA MA30633A patent/MA29694B1/fr unknown
- 2008-02-29 CR CR9787A patent/CR9787A/es not_active Application Discontinuation
- 2008-03-06 NO NO20081195A patent/NO20081195L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| NO20081195L (no) | 2008-04-28 |
| BRPI0614272A2 (pt) | 2011-03-22 |
| EP1912985A1 (en) | 2008-04-23 |
| WO2007017237A1 (en) | 2007-02-15 |
| MX2008001935A (es) | 2008-03-26 |
| TW200734335A (en) | 2007-09-16 |
| KR20080034457A (ko) | 2008-04-21 |
| PE20070239A1 (es) | 2007-04-01 |
| US20080221097A1 (en) | 2008-09-11 |
| CR9787A (es) | 2008-05-05 |
| IL188924A0 (en) | 2008-08-07 |
| AU2006278191A1 (en) | 2007-02-15 |
| MA29694B1 (fr) | 2008-08-01 |
| EA200800562A1 (ru) | 2008-06-30 |
| JP2009504587A (ja) | 2009-02-05 |
| CA2618165A1 (en) | 2007-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR050158A1 (es) | Compuesto derivado de pirrolopiridina, composicion farmaceutica que lo comprende y su uso para fabricar dicha composicion | |
| AR041016A1 (es) | Compuesto de pirimidina, composicion farmaceutica que lo comprende y uso del mismo para preparar dicha composicion | |
| AR065354A1 (es) | Derivados de 2-aminopirimidina, un metodo para su preparacion, una composicion farmaceutica que lo comprende y su uso en el tratamiento de enfermedades mediadas por el receptor de histamina h4. | |
| AR070268A1 (es) | Compuesto de oxa-azaspiro, su uso para la fabricacion de un medicamento para la modulacion de receptores y5 de npy y composicion farmaceutica que lo comprende | |
| AR071285A1 (es) | Pirido[3, 4-b]indoles, una composicion farmaceutica que los comprende y su uso en el tratamiento de trastornos neurologicos. | |
| WO2007017264A3 (en) | Pyrrolopyridinederivatives as modulators of the cannabinoid receptor for the treatment of immune and inflammatory disorders | |
| CL2014003181A1 (es) | Compuestos derivados de benzamidas n- sustituidas o piridinamidas n-sustituidas; composicion farmaceutica que los comprende; metodo de tratamiento; y su uso para el tratamiento de enfermedades o trastornos seleccionados de dolor, depresion y enfermedades cardiovasculares, respiratorias o psiquiatricas o combinaciones de estas. | |
| AR078522A1 (es) | Compuesto de espiropiperidina, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para tratar diabetes y compuesto intermediario para su sintesis | |
| AR041395A1 (es) | Compuesto de piridina composicion farmaceutica que lo comprende y su uso para prepararla | |
| TNSN07471A1 (en) | Novel 2,4 - dianilinopyrimidine derivatives, the preparation thereof, their use as medicaments, pharmaceutical compositions and, in particular, as ikk inhibitors | |
| AR065806A1 (es) | Derivados de quinolina, procesos para su preparacion, composiciones farmaceuticas que los contienen y usos para el tratamiento de la artritis reumatoidea. | |
| BRPI0817096A8 (pt) | Análogo de tiazolidinodiona e composição farmacêutica que o compreende | |
| MA32175B1 (fr) | Oxadiazoanthracènes pour le traitement du diabète | |
| AR075104A1 (es) | Compuesto de piperazin-aril-purina, su uso para preparar un medicamento util para el tratamiento del dolor y composicion farmaceutica que lo comprende | |
| AR039219A1 (es) | Compuestos imidazo-sustituidos | |
| ECSP14004812A (es) | Triazolopiridinas sustituidas | |
| BRPI0821235A2 (pt) | Composição de moldagem termoplástica, usos de composto e de composição de moldagem termoplástica, e, fibra, folha, ou uma moldagem. | |
| HRP20241020T1 (hr) | Makrociklički spoj koji služi kao wee1 inhibitor i njegove primjene | |
| EA201690072A1 (ru) | Состав, содержащий гиполипидемическое средство | |
| CY1108880T1 (el) | Παραγωγα καρβοξαμιδιου ως ανταγωνιστες μουσκαρινικου υποδοχεα | |
| AR055601A1 (es) | Compuestos derivados de imidazopiridina como ligandos de receptores canabinoides | |
| WO2008099072A3 (fr) | Nouveaux derives de 2, 4-dianilinopyrimidines, leur preparation, a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk | |
| AR077227A1 (es) | Compuesto de acido aril/ heteroaril- sustituido carboxilico, su uso para fabricar un medicamento util el tratamiento de afecciones o trastornos mediados por receptores s1p1, tales como esclerosis multiple y composicion farmaceutica que lo comprende | |
| MX2016014239A (es) | Composicion limpiadora. | |
| CO2017005416A2 (es) | Compuestos a base de fenilo sustituidos con porciones de aldehído |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |